POMP and PYGM

Data Source:
BioGRID (two hybrid)

		POMP	PYGM
Description		proteasome maturation protein	glycogen phosphorylase, muscle associated
Image		No pdb structure
GO Annotations	Cellular Component	Nucleus Cytoplasm Endoplasmic Reticulum Cytosol Nuclear Speck Organelle Membrane	Cytoplasm Cytosol Extracellular Exosome
	Molecular Function	Protein Binding	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity
	Biological Process	Proteasome Assembly	Glycogen Metabolic Process Glycogen Catabolic Process
Pathways			Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)
Drugs			Pyridoxal phosphate Beta-D-Glucopyranose Spirohydantoin (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione alpha-D-glucose 6-phosphate N-beta-D-glucopyranosylacetamide Monofluorophosphate ion Beta-D-Glucose 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Nojirimycine Tetrazole Indirubin-5-sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-hydrogyl-beta-D-glucopyranosyl) formamide alpha-D-glucopyranosyl-2-carboxylic acid amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-acetyl-N'-beta-D-glucopyranosyl urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole CP-320626 (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Alvocidib 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N(6)-(pyridoxal phosphate)-L-lysine Heptulose-2-Phosphate N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine Dexfosfoserine 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
Diseases		Keratosis linearis with ichthyosis congenita and sclerosing keratoderma; KLICK syndrome	Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GWAS		Breast cancer (menopausal hormone therapy interaction) ( 24080446) Hematocrit ( 32888494 27863252) Hemoglobin ( 32888494) Hemoglobin concentration ( 27863252) Hemoglobin levels ( 32327693) Red blood cell count ( 32888494) Refractive error ( 32231278)	Urate levels ( 21768215)
Interacting Genes		25 interacting genes: ARMT1 ATXN1 CAPN3 ECT2 FAM107A GPD1 GRB2 KCNA10 KIF1B KLHL41 MPPED2 PSMA1 PSMA3 PSMB1 PSMB10 PSMB5 PSMB6 PSMB7 PSMB8 PSMB9 PYGM RBM5 SSR4 TTN VCL	29 interacting genes: AGTPBP1 ARID1B CDC42BPB CLASP2 DNM2 FAM110A IGBP1 INTS4 LMNA NIPSNAP2 NTAQ1 PDE4DIP POMP PPP1CA PPP1R3B PPP2CA PRKAB2 PYGB PYGL S100A1 SGCG SRP72 TOP1 TRAPPC2 TRIM54 TRIM55 TRIM63 TTN WWP1
Entrez ID		51371	5837
HPRD ID		12613	01986
Ensembl ID		ENSG00000132963	ENSG00000068976
Uniprot IDs		Q9Y244	P11217
PDB IDs			1Z8D
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?